Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Payables: 2024-2025

Historic Payables for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $66.8 million.

  • Kura Oncology's Payables rose 80.67% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.8 million, marking a year-over-year change of. This contributed to the annual value of $50.0 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Payables amounted to $66.8 million in Q3 2025, which was up 26.18% from $52.9 million recorded in Q2 2025.
  • Kura Oncology's 5-year Payables high stood at $66.8 million for Q3 2025, and its period low was $30.9 million during Q1 2024.
  • In the last 2 years, Kura Oncology's Payables had a median value of $45.1 million in 2025 and averaged $44.8 million.
  • Data for Kura Oncology's Payables shows a peak YoY surged of 80.67% (in 2025) over the last 5 years.
  • Kura Oncology's Payables (Quarterly) stood at $50.0 million in 2024, then skyrocketed by 80.67% to $66.8 million in 2025.
  • Its last three reported values are $66.8 million in Q3 2025, $52.9 million for Q2 2025, and $45.1 million during Q1 2025.